# OnCo record pituitary-tumours (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/pituitary-tumours/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "pituitary-tumours" ;
  schema:name "Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma"@en ;
  schema:alternateName "Pituitary adenoma"@en, "PitNET"@en, "Prolactinoma"@en, "Acromegaly"@en, "Cushing disease"@en, "Pituitary carcinoma"@en ;
  schema:description "Pituitary tumours are usually benign growths of the hormone gland at the base of the brain that cause trouble by overproducing hormones or pressing on the optic nerves. Prolactin-producing tumours melt away with a tablet, most others are cured by surgery through the nose, and the rare aggressive ones respond to the chemotherapy drug temozolomide."@en ;
  schema:url <https://onco.cc/cancers/pituitary-tumours/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pituitary_adenoma> ;
  schema:citation <https://www.cancer.gov/types/pituitary>, <https://doi.org/10.1530/EJE-17-0796>, <https://doi.org/10.1038/s41574-023-00886-5> ;
  onco:tag "nci-coverage", "rare", "endocrine", "cns" ;
  onco:related <https://onco.cc/cancers/craniopharyngioma/>, <https://onco.cc/cancers/meningioma/>, <https://onco.cc/cancers/vestibular-schwannoma/>, <https://onco.cc/cancers/cns-germ-cell-tumours/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/prrt/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/sstr2/> ;
  onco:drugs <https://onco.cc/drugs/octreotide-lanreotide/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/lutathera/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/bromocriptine/>, <https://onco.cc/drugs/cabergoline/>, <https://onco.cc/drugs/pasireotide/>, <https://onco.cc/drugs/pegvisomant/>, <https://onco.cc/drugs/osilodrostat/>, <https://onco.cc/drugs/metyrapone/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:terms <https://onco.cc/terms/mgmt/>, <https://onco.cc/terms/rare-cancers/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-overdiagnosis/>, <https://onco.cc/bottlenecks/b-rare-cancers/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-petersenn-nat-rev-endocrinol/>, <https://onco.cc/key-papers/paper-raverot-eur-j-endocrinol/> ;
  onco:pipeline <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/technologies/prrt/>, <https://onco.cc/technologies/sbrt/> ;
  onco:standardOfCare <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/drugs/octreotide-lanreotide/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/technologies/prrt/>, <https://onco.cc/drugs/lutathera/>, <https://onco.cc/drugs/bevacizumab/> .